ProCertus BioPharm, Inc. is an oncology-based pharmaceutical company established in 1997 with administrative and research facilities located in Madison, Wisconsin. The ProCertus mission is:
To discover and develop innovative pharmaceutical products that protect cancer patients against the side effects of their therapy.
The Company holds exclusive world-wide license to a breakthrough technology platform based upon the research and development activities of Dr. William E. Fahl, a world-recognized expert in cancer research with the McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison.
Based on a common technology platform, the Company has developed DermX, ProDermaCelÔ and OralX in parallel through animal proof of concept, and will advance all three product candidates to safety and efficacy studies in normal human subjects and cancer patients.
ProCertus management believes that ProDermaCelÔ, DermX, and OralX will fundamentally change the quality of life for cancer patients.
